Bis-cyclic Guanidine Antibiotics Against ESKAPE Pathogens
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an alarming decline in drug discovery efforts for treating drug-resistant ESKAPE pathogen isolates, leading to a need for new antibacterial agents effective against pathogens like Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter cloacae, which are resistant to existing treatments.
Innovation Solution
Development of bis-cyclic guanidine compounds as broad-spectrum antibiotics, which are synthesized and formulated into pharmaceutical compositions to treat bacterial infections and inhibit biofilm growth, with structures including specific R1, R2, and R3 groups, demonstrating strong antibacterial activity and low toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antibacterial drugs are used, then treatment of common bacterial infections is effective, but they are ineffective against drug-resistant ESKAPE pathogen isolates
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of guanidine compounds through systematic variation of R1, R2, and R3 substituents. This structural parameter optimization enables the compounds to maintain efficacy against drug-resistant ESKAPE pathogens while preserving low toxicity, directly resolving the contradiction between reliability against resistant strains and adaptability across different pathogen types.
Solution Approach 2:
The invention creates composite molecular structures by combining the bis-cyclic guanidine core with diverse hydrophobic substituents (R1, R2, R3 groups). This composite approach generates compounds with enhanced broad-spectrum activity against ESKAPE pathogens, effectively addressing the limitation of existing drugs that fail against resistant isolates while maintaining selective toxicity.
2Adaptability or versatility
If broad-spectrum antibiotics are developed to treat multiple resistant pathogens, then coverage of ESKAPE pathogens is improved, but risk of resistance development increases
Solution Approach 1:
The patent applies local quality by designing bis-cyclic guanidine compounds with specific localized functional groups (R1, R2, R3 substituents) that confer broad-spectrum activity against ESKAPE pathogens. The molecular structure features distinct regions with optimized properties: the core guanidine moiety provides broad coverage while specific substituent patterns minimize resistance development, thus resolving the contradiction between versatility and reliability.
3Reliability
If new antibacterial compounds are synthesized to overcome resistance, then efficacy against ESKAPE pathogens is improved, but toxicity to human cells may increase
Solution Approach 1:
The patent utilizes parameter changes by systematically optimizing the R1, R2, and R3 substituents on the bis-cyclic guanidine core to achieve the desired balance between antibacterial activity and cytotoxicity. Specific parameter ranges for hydrophobicity, molecular weight, and substituent positioning are identified to maximize efficacy against ESKAPE pathogens while maintaining low toxicity to human cells, directly resolving this contradiction.
Data Source
AI summary
The present disclosure provides compositions including a bis-cyclic guanidine compound, pharmaceutical compositions including a bis-cyclic guanidine compound, methods of treatment of a condition (e.g., bacterial infection) or disease, methods of treatment using compositions or pharmaceutical compositions, and the like.